Direkt zum Inhalt
Merck

1356960

USP

Leflunomid

United States Pharmacopeia (USP) Reference Standard

Synonym(e):

5-Methylisoxazol-4-(4-trifluormethyl)-carboxanilid

Anmelden zur Ansicht der Organisations- und Vertragspreise.

Größe auswählen

200 MG

€ 481,00

€ 481,00


Warenkorb auf Verfügbarkeit prüfen

Großbestellung anfragen

Über diesen Artikel

Empirische Formel (Hill-System):
C12H9F3N2O2
CAS-Nummer:
Molekulargewicht:
270.21
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:

Fortfahren mit

Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhalten

InChI

1S/C12H9F3N2O2/c1-7-10(6-16-19-7)11(18)17-9-4-2-8(3-5-9)12(13,14)15/h2-6H,1H3,(H,17,18)

SMILES string

Cc1oncc1C(=O)Nc2ccc(cc2)C(F)(F)F

InChI key

VHOGYURTWQBHIL-UHFFFAOYSA-N

grade

pharmaceutical primary standard

API family

leflunomide

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

Gene Information

human ... DHODH(1723)

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Ähnliche Artikel vergleichen

Vollständigen Vergleich anzeigen

Unterschiede anzeigen

1 of 4

Dieser Artikel
PHR1378Y0000654BP1233
Leflunomide United States Pharmacopeia (USP) Reference Standard

USP

1356960

Leflunomide

Leflunomide European Pharmacopoeia (EP) Reference Standard

Y0000654

Leflunomide

Leflunomide British Pharmacopoeia (BP) Reference Standard

BP1233

Leflunomide

grade

pharmaceutical primary standard

grade

certified reference material, pharmaceutical secondary standard

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

manufacturer/tradename

USP

manufacturer/tradename

-

manufacturer/tradename

EDQM

manufacturer/tradename

BP

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical
pharmaceutical small molecule

format

neat

format

neat

format

neat

format

neat

API family

leflunomide

API family

leflunomide

API family

leflunomide

API family

leflunomide

Gene Information

human ... DHODH(1723)

Gene Information

human ... DHODH(1723)

Gene Information

human ... DHODH(1723)

Gene Information

human ... DHODH(1723)

General description

Leflunomide is a drug with cytotoxic properties.[1] It is generally used as an immunosuppressive agent.[2]

Application

Leflunomide USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

pictograms

Skull and crossbones

signalword

Danger

Hazard Classifications

Acute Tox. 3 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

Lagerklasse

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

flash_point_f

Not applicable

flash_point_c

Not applicable


Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Dokumente section.

Wenn Sie Hilfe benötigen, wenden Sie sich bitte an Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

S Greene et al.
Biochemical pharmacology, 50(6), 861-867 (1995-09-07)
Leflunomide [HWA 486 or RS-34821, 5-methyl-N-(4-trifluoromethylphenyl)-4-isoxazole carboximide] is an immunosuppressive agent effective in the treatment of rheumatoid arthritis. In spite of its clinical potential, its mechanism of action has not been elucidated. Recent studies suggest that leflunomide may interfere with
Robert P Baughman et al.
Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 21(1), 43-48 (2004-05-07)
Leflunomide (Arava) is a cytotoxic drug which has been used as a single agent or in combination with methotrexate for the treatment of rheumatoid arthritis. It appears to have less toxicity than methotrexate. The use of leflunomide for sarcoidosis patients
Nicola Alcorn et al.
Drug safety, 32(12), 1123-1134 (2009-11-18)
Evidence is accumulating for the early sustained usage of disease-modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis. Leflunomide was licensed for the treatment of rheumatoid arthritis in 1998. Postmarketing surveillance, case reports and observational studies have highlighted less common or unexpected
Frank Behrens et al.
Current opinion in rheumatology, 23(3), 282-287 (2011-03-24)
Leflunomide is often used as a first choice disease-modifying antirheumatic drug after methotrexate. New data are available for efficacy and safety in both, monotherapy and combination with biologicals. New data on efficacy demonstrate comparable effect sizes for leflunomide and methotrexate
W James Chon et al.
Expert review of clinical immunology, 7(3), 273-281 (2011-05-21)
Leflunomide is a synthetic isoxazole-derivative drug that possesses both immunosuppressive and antiviral properties. Although its only US FDA-approved indication is for the treatment of rheumatoid arthritis, accumulating clinical experience in addition to animal study data makes it an appealing option

Questions

Reviews

No rating value

Active Filters

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung